Vericel Corp. (VCEL)
40.15
+0.71
(+1.80%)
USD |
NASDAQ |
Oct 02, 16:00
40.15
0.00 (0.00%)
After-Hours: 20:00
Vericel Net Income (Quarterly) : 2.206M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.206M |
| March 31, 2026 | -6.302M |
| December 31, 2025 | 23.24M |
| September 30, 2025 | 5.074M |
| June 30, 2025 | -0.553M |
| March 31, 2025 | -11.25M |
| December 31, 2024 | 19.81M |
| September 30, 2024 | -0.901M |
| June 30, 2024 | -4.682M |
| March 31, 2024 | -3.862M |
| December 31, 2023 | 12.99M |
| September 30, 2023 | -3.66M |
| June 30, 2023 | -5.02M |
| March 31, 2023 | -7.495M |
| December 31, 2022 | 5.922M |
| September 30, 2022 | -6.577M |
| June 30, 2022 | -8.963M |
| March 31, 2022 | -7.091M |
| December 31, 2021 | 4.535M |
| September 30, 2021 | -4.931M |
| June 30, 2021 | -3.786M |
| March 31, 2021 | -3.289M |
| December 31, 2020 | 12.22M |
| September 30, 2020 | 3.618M |
| June 30, 2020 | -8.269M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.705M |
| December 31, 2019 | 9.501M |
| September 30, 2019 | 3.47M |
| June 30, 2019 | -19.79M |
| March 31, 2019 | -2.844M |
| December 31, 2018 | 5.242M |
| September 30, 2018 | -1.069M |
| June 30, 2018 | -4.651M |
| March 31, 2018 | -7.659M |
| December 31, 2017 | 0.287M |
| September 30, 2017 | -5.407M |
| June 30, 2017 | -2.388M |
| March 31, 2017 | -9.778M |
| December 31, 2016 | -6.197M |
| September 30, 2016 | -6.675M |
| June 30, 2016 | -3.044M |
| March 31, 2016 | -3.65M |
| December 31, 2015 | -4.91M |
| September 30, 2015 | -4.416M |
| June 30, 2015 | -2.152M |
| March 31, 2015 | -4.862M |
| December 31, 2014 | -2.37M |
| September 30, 2014 | -6.917M |
| June 30, 2014 | -4.638M |
| March 31, 2014 | -7.413M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| ADMA Biologics, Inc. | 37.82M |
| Kyntra Bio, Inc. | 11.97M |
| Conexeu Sciences, Inc. | -7.726M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 77.46M |
| Total Expenses (Quarterly) | 75.25M |
| EPS Diluted (Quarterly) | 0.0422 |
| Enterprise Value | 1.987B |
| Gross Profit Margin (Quarterly) | 72.82% |
| Profit Margin (Quarterly) | 2.85% |
| Earnings Yield | 1.15% |
| Operating Earnings Yield | 0.88% |
| Normalized Earnings Yield | 1.151 |